US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Alpine Immune Sciences, Inc. - Common Stock (NQ:ALPN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alpine Immune Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
From Kahn Swick & Foti, LLC
Via Business Wire
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 4/16
Via Investor Brand Network
News headline image
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
From Kahn Swick & Foti, LLC
Via Business Wire
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 3/19
Via Investor Brand Network
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 3/8
Via Investor Brand Network
Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 2/29
Via Investor Brand Network
Alpine Immune Sciences Inc. (NASDAQ: ALPN) Near Top of Volume Charts in Thursday Trading
Via Investor Brand Network
Alpine Immune Sciences Inc. (NASDAQ: ALPN) Records 52-Week High Thursday Morning
Via Investor Brand Network
News headline image
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >